Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Among authors: moffett k. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
Differences in social media use by COVID-19 vaccination status.
Moffett KW, Seserman K, Margolis KA, Kranzler EC, Marshall MC, Dahlen H, Kim JC, Denison B, Hoffman B, Dupervil D, Yu K, Hoffman L. Moffett KW, et al. Vaccine. 2024 Apr 2;42(9):2166-2170. doi: 10.1016/j.vaccine.2024.03.031. Epub 2024 Mar 20. Vaccine. 2024. PMID: 38514356 Free article.
Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting.
Albon D, Thomas L, Hoberg L, Stamper S, Somerville L, Varghese P, Balasa E, Roman M, Britto MT, Miner M, Gehring E, Gammon C, Amin RS, Seid M, Powers M; CF Learning Network telehealth iLab working group. Albon D, et al. BMJ Open Qual. 2022 May;11(2):e001844. doi: 10.1136/bmjoq-2022-001844. BMJ Open Qual. 2022. PMID: 35589277 Free PMC article.
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Cystic Fibrosis and COVID-19.
Chapman KD, Moffett KS. Chapman KD, et al. Among authors: moffett ks. South Med J. 2020 Sep;113(9):422. doi: 10.14423/SMJ.0000000000001140. South Med J. 2020. PMID: 32885259 Free PMC article. No abstract available.
62 results